In vitro experiments, we found that metabolic reprogramming can promote the production of acidic microenvironment by releasing lactic acid into the tumor microenvironment, and then up-regulate the expression of FcγRIIB on M2 macrophages, leading to CD8+T cell dysfunction and PD-1 antibody treatment resistance. The gene discussed is FCGR2B; the disease is neoplasm.